s-adenosyl-methionine and betaine improve early virological response in chronic hepatitis c patients with previous nonresponses-adenosyl-methionine和甜菜碱提高早期病毒学反应在慢性丙型肝炎患者先前nonresponse.pdfVIP

s-adenosyl-methionine and betaine improve early virological response in chronic hepatitis c patients with previous nonresponses-adenosyl-methionine和甜菜碱提高早期病毒学反应在慢性丙型肝炎患者先前nonresponse.pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
s-adenosyl-methionine and betaine improve early virological response in chronic hepatitis c patients with previous nonresponses-adenosyl-methionine和甜菜碱提高早期病毒学反应在慢性丙型肝炎患者先前nonresponse

S-Adenosyl-Methionine and Betaine Improve Early Virological Response in Chronic Hepatitis C Patients with Previous Nonresponse 1,2 1,2 3 1 Magdalena Filipowicz , Christine Bernsmeier , Luigi Terracciano , Francois H. T. Duong , Markus H. Heim1,2* 1 Hepatology Laboratory, Department of Biomedicine, University Hospital Basel, Basel, Switzerland, 2 Department of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland, 3 Institute for Pathology, University Hospital Basel, Basel, Switzerland Abstract Background/Aims: Treatment of chronic hepatitis C (CHC) with pegylated interferon a (pegIFNa) and ribavirin results in a sustained response in approximately half of patients. Viral interference with IFNa signal transduction through the Jak-STAT pathway might be an important factor underlying treatment failure. S-adenosyl-L-methionine (SAMe) and betaine potentiate IFNa signaling in cultured cells that express hepatitis C virus (HCV) proteins, and enhance the inhibitory effect of IFNa on HCV replicons. We have performed a clinical study with the aim to evaluate efficacy and safety of the addition of SAMe and betaine to treatment of CHC with pegIFNa/ribavirin. Methods: In this open-label pilot study, 29 patients with CHC who failed previous therapy with (peg)IFNa/ribavirin were treated with SAMe, betaine, pegIFNa2b and ribavirin. Treatment duration was 6 or 12 months, depending on genotype, and the protocol comprised a stopping rule at week 12 if early virological response (EVR) was not achieved. Virological and biochemical response and safety were assessed throughout the treatment. Results: 29 patients were enrolled and treated according to the

您可能关注的文档

文档评论(0)

xyz118 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档